Synapse - David Hyman

Results (18)

Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers

Journal Article

Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
Investigational New Drugs (2021)

Fulltext@MSK | Save

Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation

Meeting Abstract

Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
Pediatric Blood and Cancer (2020)

Fulltext@MSK | Save

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

Journal Article

Durham, B. H.; Lopez Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S. X.; Pastore, A.; Yoshimi, A.; more...
Nature Medicine (2019)

Fulltext@MSK | Save

Efficacy of MEK inhibition in patients with histiocytic neoplasms

Journal Article

Diamond, E. L.; Durham, B. H.; Ulaner, G. A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R. J.; Francis, J. H.; more...
Nature (2019)

Fulltext@MSK | Save

Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study

Journal Article

Diamond, E. L.; Subbiah, V.; Lockhart, A. C.; Blay, J. Y.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J.; Erinjeri, J. P.; Torrisi, J.; more...
JAMA Oncology (2018)

Fulltext@MSK | Save

Single-agent dabrafenib for BRAF(V600E)-mutated histiocytosis

Journal Article

Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D. M.; Abdel-Wahab, O.; Durham, B. H.; Dogan, A.; Ozkaya, N.; Lacouture, M. E.; Hajdenberg, J.; more...
Haematologica (2018)

Fulltext@MSK | Save

First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study

Journal Article

Sullivan, R. J.; Infante, J. R.; Janku, F.; Lee Wong, D. J.; Sosman, J. A.; Keedy, V.; Patel, M. R.; Shapiro, G. I.; Mier, J. W.; Tolcher, A. W.; more...
Cancer Discovery (2018)

Fulltext@MSK | Save

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

Meeting Abstract

Li, B. T.; Janku, F.; Patel, M. R.; Sullivan, R. J.; Flaherty, K.; Buchbinder, E. I.; Lacouture, M. E.; Varghese, A. M.; Wong, D. J. L.; Sznol, M.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Journal Article

Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
Investigational New Drugs (2017)

Fulltext@MSK | Save

Vemurafenib in patients with Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) harboring BRAF(V600) mutations: A cohort of the histology-independent VE-BASKET study

Meeting Abstract

Diamond, E. L.; Subbiah, V.; Lockhart, C.; Blay, J. Y.; Faris, J. E.; Puzanov, I.; Chau, I.; Raje, N. S.; Wolf, J. S.; Erinjeri, J.; more...
Blood (2016)

Fulltext@MSK | Save